ALC — Alcon Inc. stock price, charts and financials

QT41Alcon Inc.

Alcon Inc. (NYSE: ALC) is a Healthcare company in the Medical - Specialties industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
65.04
-0.14-0.21%
ALCQT41Alcon Inc.·NYSE
65.04-0.21%
TA
Loading chart...
Screen all →
Snapshot
Index-P/E50.03EPS (ttm)1.30Insider Own-Shs Outstand487.70MPerf Week-1.50%
Market Cap31.72BForward P/E16.71EPS next Y3.89Insider Trans-Shs Float486.14MPerf Month-12.42%
Enterprise Value35.66BPEG-EPS next Q0.89Inst Own-Short Float3.00%Perf Quarter0.56%
Income640.74MP/S2.93EPS this Y107.88%Inst Trans-Short Ratio7.50Perf Half Y-13.29%
Sales10.81BP/B1.47EPS next Y13.46%ROA2.06%Short Interest14.57MPerf YTD-17.47%
Book/sh-P/C13.90EPS next 5Y12.70%ROE2.91%52W High87.64 -25.79%Perf Year-15.75%
Cash/sh-P/FCF18.84EPS past 3/5Y42.80% -ROIC3.24%52W Low61.84 5.17%Perf 3Y-19.92%
Dividend Est.0.36 (0.55%)EV/EBITDA17.65Sales past 3/5Y6.06% 8.77%Gross Margin56.45%Volatility1.86% 1.62%Perf 5Y-22.39%
Dividend TTM0.36 (0.55%)EV/Sales3.30EPS Y/Y TTM-19.51%Oper. Margin9.87%ATR (14)1.45Perf 10Y-
Dividend Ex-DateMay 06, 2026Quick Ratio1.30Sales Y/Y TTM6.76%Profit Margin5.92%RSI (14)30.63Recom2.54
Dividend Gr. 3/5Y17.60% -Current Ratio2.09EPS Q/Q10.53%SMA20-6.98%Beta0.87Target Price73.43
Payout26.38%Debt/Eq0.25Sales Q/Q8.74%SMA50-7.42%Rel Volume1.79Prev Close65.18
Employees25,000LT Debt/Eq0.21EarningsNov 10SMA200-12.10%Avg Volume1.93MPrice65.04
IPO DateApr 09, 2019Option/ShortYes / YesEPS/Sales Surpr.12.33% 2.54%Net Debt/EBITDA1.95Volume3,443,196Change-0.21%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-13-26ReiteratedBNP Paribas$79
Aug-12-26ReiteratedUBSBuy$91$35
Aug-12-26ReiteratedMizuhoOutperform$80$85
Aug-11-26ReiteratedBTIGBuy$100$82
Jul-15-26ReiteratedMizuhoOutperform$105$80
Jul-02-26ReiteratedArgus ResearchBuy$90$85
May-08-26ReiteratedBarclaysEqual Weight$86$78
May-06-26ReiteratedStifel Nicolaus$82$70
Mar-09-26ReiteratedStifel Nicolaus$80$82
Feb-26-26UpgradeWells FargoEqual WeightOverweight$105$97
Latest News· Times ET
Sep-15-26
Sep-08-26
Sep-04-26
Sep-03-26
Sep-03-2605:07AM
Sep-01-26
Aug-26-26
Aug-24-26
Aug-17-26
Aug-13-26
10:27AM
Aug-12-26
Company

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue10,58110,4019,911
Cost of Goods Sold Incl. D&A4,7674,6564,399
Gross Profit5,8145,7455,512
Selling, General and Administrative Excl. Other3,4803,4493,250
Research and Development1,008990876
Other Operating Expense24-54-27
Operating Income1,3031,3601,413
Interest Expense206204186
Unusual Expense
Non-Operating Income (Expense)-116429
Net Income Before Taxes9811,1601,256
Income Taxes166180238
Consolidated Net Income8159801,018
Net Income From Continuing Operations8159801,018
Net Income8159801,018
EPS (Recurring)1.661.992.06
EPS (Basic, Before Extraordinaries)1.661.992.06
EPS (Diluted)1.651.982.05
EBITDA2,3632,3512,676
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio39.4239.8041.41
Price To Sales Ratio2.993.754.23
Gross Margin54.9555.2455.61
Operating Margin12.3113.0814.26
Net Margin7.709.4210.27
Shares Outstanding487495494
Market Capitalization31,67439,01141,936
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.